Enveric Biosciences, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ENVB research report →
Price Chart
About the company
Enveric Biosciences, Inc. is a pharmaceutical firm focused on advancing diverse cannabinoid-based medications, primarily for use in cancer care. The company's robust product pipeline includes EV104, developed for treating osteoarthritis, and EVM-101 and EVM-201, which are intended to alleviate cancer-related distress.
- CEO
- Joseph Edward Tucker
- IPO
- 2015
- Employees
- 6
- HQ
- Cambridge, MA, US
Get TickerSpark's AI analysis on ENVB
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $829.85K
- P/E
- -0.08
- PEG
- -0.00
- P/S
- 0.00
- P/B
- 0.69
- EV/EBITDA
- 0.87
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -168.05%
- ROIC
- -107.99%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $-200,858+40.5%
- Op Income
- $-8,774,448
- Net Income
- $-12,131,472-26.7%
- EPS
- $-36.24+84.1%
- OCF Growth
- -5.4%
- FCF Growth
- -5.4%
- 52W High
- $17.64
- 52W Low
- $1.25
- 50D MA
- $1.43
- 200D MA
- $3.02
- Beta
- 1.13
- RSI (14)
- 44
- Avg Volume
- 158.43K
No earnings-call transcripts are available for ENVB yet.
- Free Float
- 91.4%
- Shares Outstanding
- 597.01K
- Float Shares
- 545.87K
of shares held by institutions
11 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Blackrock Inc. | 29.58K | 0 |
Held by 5 ETFs
Biggest fund positions in ENVB by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Dec 23, 25 | DeWitt Sheila | other | 7,633 |
| Dec 23, 25 | Kegler George A. | other | 7,633 |
| Dec 23, 25 | PASQUALONE FRANK | other | 7,633 |
| Dec 23, 25 | Schabacker Marcus | other | 7,633 |
| Dec 23, 25 | Tucker Joseph Edward | other | 60,296 |
| Dec 23, 25 | WEBB MICHAEL D | other | 7,633 |
| Dec 23, 25 | Coveney Kevin Michael | other | 40,198 |
| May 8, 25 | Coveney Kevin Michael | other | 74,150 |
| May 8, 25 | Facchini Peter J. | other | 24,717 |
| May 8, 25 | Tucker Joseph Edward | other | 98,866 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our ENVB coverage
Recent articles, reports, and earnings notes.
No research on ENVB yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate ENVB report →Enveric Biosciences Reports Financial Results and Provides Corporate Update for Second Quarter 2026
businesswire.com · Aug 14
Enveric Biosciences Says New Preclinical Data Confirms Non-Hallucinogenic Profile For Lead Psychiatric Candidate
benzinga.com · Aug 5
Enveric Biosciences Reports New Preclinical Data Supporting the Non-Hallucinogenic Profile of Lead Candidate EB-003
businesswire.com · Aug 5
Enveric Biosciences Welcomes Final FDA Guidance for Psychedelic Drug Development
businesswire.com · Jul 28
Enveric Biosciences Announces Participation in B. Riley Securities Mind, Muscle & Vision Summit
businesswire.com · Jun 29
Enveric Biosciences Announces Participation in 2026 BIO International Convention
gurufocus.com · Jun 16
Enveric Biosciences Announces Participation in 2026 BIO International Convention
businesswire.com · Jun 16
Enveric Biosciences to Participate in the UBS 3rd Virtual CNS Day
businesswire.com · Jun 9
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.